| [1]Holland IB, Blight MA.ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans[J].J Mol Biol, 1999, 293(2):381-399[2]Reese MJ, Savina PM, Generaux GT, et al.In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor[J].Drug Metab Dispos, 2013, 41(2):353-361[3]Rochat B.Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents[J].Curr Cancer Drug Targets, 2009, 9(5):652-674[4]Rice AJ, Park A, Pinkett HW.Diversity in ABC transporters: type I,II and III importers[J].Crit Rev Biochem Mol Biol, 2014, 49(5):426-437[5]ter Beek J, Guskov A, Slotboom DJ.Structural diversity of ABC transporters[J].J Gen Physiol, 2014, 143(4):419-435[6]Wang S, Qiu J, Shi Z, et al.Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer[J].Biotechnol Adv, 2015, 33(1):224-241[7]Baker A, Carrier DJ, Schaedler T, et al.Peroxisomal ABC transporters: functions and mechanism[J].Biochem Soc Trans, 2015, 43(5):959-965[8]Jones PM, George AM.A reciprocating twin-channel model for ABC transporters[J].Q Rev Biophys, 2014, 47(3):189-220[9]Eitinger T, Rodionov DA, Grote M, et al.Canonical and ECF-type ATP-binding cassette importers in prokaryotes: diversity in modular organization and cellular functions[J].FEMS Microbiol Rev, 2011, 35(1):3-67[10]Rees DC, Johnson E, Lewinson O.ABC transporters: the power to change[J].Nat Rev Mol Cell Biol, 2009, 10(3):218-227[11]Chen J.Molecular mechanism of the Escherichia coli maltose transporter[J].Curr Opin Struct Biol, 2013, 23(4):492-498[12]Montanari F, Ecker GF.Prediction of drug-ABC-transporter interaction--Recent advances and future challenges[J].Adv Drug Deliv Rev, 2015, 86:17-26[13]Chen Z, Shi T, Zhang L, et al.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade[J].Cancer Lett, 2016, 370(1):153-164[14]Theodoulou FL, Kerr ID.ABC transporter research: going strong 40 years on[J].Biochem Soc Trans, 2015, 43(5):1033-1040[15]Levati? J, ?urak J, Kralj M,et al.Accurate models for P-gp drug recognition induced from a cancer cell line cytotoxicity screen[J].J Med Chem, 2013, 56(14):5691-5708[16]Borst P, Schinkel AH.P-glycoprotein ABCB1: a major player in drug handling by mammals[J].J Clin Invest, 2013, 123(10):4131-4133[17]Tsujimura S, Tanaka Y.Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis[J].World J Exp Med, 2015, 5(4):225-231[18]Cui C, Xue YN, Wu M, et al.Cellular uptake,intracellular trafficking,and antitumor efficacy of doxorubicin-loaded reduction-sensitive micelles[J].Biomaterials, 2013, 34(15):3858-3869[19]Sharom FJ.Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function[J].Front Oncol, 2014, 4:41-59[20]Bao L, Haque A, Jackson K, et al.Increased of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model[J].Am J Pathol, 2011, 178(2):838-852[21]Nabekura T, Hiroi T, Kawasaki T, et al.Effects of natural nuclear factor-kappa B inhibitors on anticancer drug efflux transporter human P-glycoprotein[J].Biomed Pharmacother, 2015, 70:140-145[22]Kruh GD, Belinsky MG.The MRP family of drug efflux pumps[J].Oncogene, 2003, 22(47):7537-7552[23]Cole SP.Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future[J].Annu Rev Pharmacol Toxicol, 2014, 54:95-117[24]Bakos E, Evers R, Szakács G,et al.Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain[J].J Biol Chem, 1998, 273(48):32167-32175[25]尹继业，张建亭.MRP1/ABCC1基因多态性:从发现到临床应用[J].中南大学学报（医学版）, 2011, 36(10):927-938[26]Kunická T, Sou?ek P.Importance of ABCC1 for cancer therapy and prognosis[J].Drug Metab Rev, 2014, 46(3):325-342[27]Bagnoli M, Beretta GL, Gatti L, et al.Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma[J].Biomed Res Int, 2013, 2013:143202-[28]Cole SP, Deeley RG.Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP[J].Bioessays, 1998, 20(11):931-940[29]Zaman GJ, Flens MJ, van Leusden MR,et al.The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump[J].Proc Natl Acad Sci U S A, 1994, 91(19):8822-8826[30]Mo W, Zhang JT.Human ABCG2: structure, function, and its role in multidrug resistance[J].Int J Biochem Mol Biol, 2012, 3(1):1-27[31]Mao Q, Unadkat JD.Role of the breast cancer resistance protein (BCRPABCG2) in drug transport--an update[J].AAPS J, 2015, 17(1):65-82[32]Noguchi K, Katayama K, Sugimoto Y.Human ABC transporter ABCG2/BCRP in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics[J].Pharmgenomics Pers Med, 2014, 7:53-64[33]Natarajan K, Xie Y, Baer MR, et al.Role of breast cancer resistance protein (BCRPABCG2) in cancer drug resistance[J].Biochem Pharmacol, 2012, 83(8):1084-1103[34]Otero JA, Miguel V, Gonzalez-Lobato L, et al.Effect of bovine ABCG2 polymorphism Y581S SNP on secretion into milk of enterolactone, riboflavin and uric acid[J].Animal, 2016, 10(2):238-247[35]Westover D, Li F.New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies[J].J Exp Clin Cancer Res, 2015, 34:159-167[36]Jung KA, Choi BH, Kwak MK.The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2[J].Mol Pharmacol, 2015, 87(3):465-476[37]Palasuberniam P, Yang X, Kraus D, et al.ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy[J].Sci Rep, 2015, 5:13298-[38].? |
